Department of Pediatrics, Clinical Sciences, Lund University, Lasarettsgatan 40, 22185, Lund, Sweden.
Department of Oncogenomics, University Medical Center, AMC, University of Amsterdam, Amsterdam, The Netherlands.
Sci Rep. 2021 Mar 5;11(1):5307. doi: 10.1038/s41598-021-84502-4.
Up to 10% of pediatric cancer patients harbor pathogenic germline variants in one or more cancer susceptibility genes. A recent study from the US reported pathogenic variants in 22 out of 60 analyzed autosomal dominant cancer susceptibility genes, implicating 8.5% of pediatric cancer patients. Here we aimed to assess the prevalence of germline pathogenic variants in these 22 genes in a population-based Swedish cohort and to compare the results to those described in other populations. We found pathogenic variants in 10 of the 22 genes covering 3.8% of these patients. The prevalence of TP53 mutations was significantly lower than described in previous studies, which can largely be attributed to differences in tumor diagnosis distributions across the three cohorts. Matched family history for relatives allowed assessment of familial cancer incidence, however, no significant difference in cancer incidence was found in families of children carrying pathogenic variants compared to those who did not.
多达 10%的儿科癌症患者携带一种或多种癌症易感性基因的致病性种系变异。最近美国的一项研究报告称,在分析的 60 个常染色体显性癌症易感性基因中,有 22 个存在致病性变异,这意味着 8.5%的儿科癌症患者存在这种情况。在这里,我们旨在评估这些 22 个基因中的种系致病性变异在基于人群的瑞典队列中的流行率,并将结果与其他人群中的描述进行比较。我们在 22 个基因中的 10 个基因中发现了致病性变异,这些患者的患病率为 3.8%。TP53 突变的患病率明显低于以前研究中描述的情况,这在很大程度上可以归因于三个队列中肿瘤诊断分布的差异。对于亲属的匹配家族史允许评估家族癌症发病率,但在携带致病性变异的儿童的家庭与没有携带致病性变异的儿童的家庭之间,未发现癌症发病率存在显著差异。